Schnell Oliver, Alawi Hasan, Battelino Tadej, Ceriello Antonio, Diem Peter, Felton Anne-Marie, Grzeszczak Wladyslaw, Harno Kari, Kempler Peter, Satman Ilhan, Vergès Bruno
Forschergruppe Diabetes e.V. at the Helmholtz Center Munich, Ingolstädter Landstrasse 1, 85764 Munich-Neuherberg, Germany.
J Diabetes Sci Technol. 2013 Mar 1;7(2):478-88. doi: 10.1177/193229681300700225.
The increasing role for structured and personalized self-monitoring of blood glucose (SMBG) in management of type 2 diabetes has been underlined by randomized and prospective clinical trials. These include Structured Testing Program (or STeP), St. Carlos, Role of Self-Monitoring of Blood Glucose and Intensive Education in Patients with Type 2 Diabetes Not Receiving Insulin, and Retrolective Study Self-Monitoring of Blood Glucose and Outcome in Patients with Type 2 Diabetes (or ROSSO)-in-praxi follow-up. The evidence for the benefit of SMBG both in insulin-treated and non-insulin-treated patients with diabetes is also supported by published reviews, meta-analyses, and guidelines. A Cochrane review reported an overall effect of SMBG on glycemic control up to 6 months after initiation, which was considered to subside after 12 months. Particularly, the 12-month analysis has been criticized for the inclusion of a small number of studies and the conclusions drawn. The aim of this article is to review key publications on SMBG and also to put them into perspective with regard to results of the Cochrane review and current aspects of diabetes management.
随机对照临床试验强调了结构化和个性化血糖自我监测（SMBG）在2型糖尿病管理中日益重要的作用。这些试验包括结构化测试项目（或STeP）、圣卡洛斯2型糖尿病患者血糖自我监测和强化教育的作用、以及2型糖尿病患者血糖自我监测与转归的回顾性研究（或ROSSO）实践随访。已发表的综述、荟萃分析和指南也支持SMBG对胰岛素治疗和非胰岛素治疗的糖尿病患者均有益的证据。一项Cochrane综述报告称，SMBG在启动后长达6个月对血糖控制有总体效果，而这种效果在12个月后被认为会消退。特别是，12个月的分析因纳入研究数量少以及得出的结论而受到批评。本文的目的是回顾关于SMBG的关键出版物，并结合Cochrane综述的结果以及糖尿病管理的当前情况对其进行审视。
